Market Overview - The Shanghai Composite Index closed at 3393.26 points, above the six-month moving average, with a change of 0.23% [1] - The total trading volume of A-shares reached 838.618 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 184 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 11.69% deviation, closing price 14.38 yuan, with a daily increase of 20.03% and turnover rate of 15.50% [1] - Haochen Medical: 8.62% deviation, closing price 3.12 yuan, with a daily increase of 9.86% and turnover rate of 6.44% [1] - Jinyinhai: 7.58% deviation, closing price 21.00 yuan, with a daily increase of 9.66% and turnover rate of 6.43% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Guangyun Technology: 7.45% deviation, closing price 14.13 yuan, with a daily increase of 9.20% and turnover rate of 4.78% [1] - Yaowang Technology: 5.93% deviation, closing price 7.12 yuan, with a daily increase of 7.88% and turnover rate of 13.64% [1] - Nuotai Biotech: 5.91% deviation, closing price 55.37 yuan, with a daily increase of 10.36% and turnover rate of 5.58% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month moving average include: - Guangdong Hongtu: just above the six-month line [1] - Xinhe Shares: just above the six-month line [1] - Songjing Shares: just above the six-month line [1]

暗盘资金一眼洞悉庄家意图>> 牙科医疗板块盘初拉升，皓宸医疗（002622）封板涨停，爱迪特（301580）涨超5%，康惠制药 （603139）、悦心健康（002162）、正海生物（300653）、国瓷材料（300285）等均涨超2%。 ...

Core Points - The stock price of Haocen Medical (002622) increased by 1.85% to 2.75 yuan as of May 30, 2025, with a total market capitalization of 2.31 billion yuan [1] - The company plans to enhance the quality management of its dental services and improve its existing medical quality management system [2] - Delun Medical has expanded its outpatient service area by nearly 10,000 square meters and increased the number of dental chairs by over 100 [3] Company Updates - As of December 31, 2024, Haocen Medical had over 1,700 employees [4] - The company will strictly follow accounting standards for impairment provisions in the second quarter [4] - Delun Medical's new outpatient clinic in Zhaoqing opened in May 2025 [4] - There are currently no plans for the company to acquire the remaining shares of Delun Medical [4]

Group 1: Company Overview and Performance - As of December 31, 2024, the company has over 1,700 employees [1] - The company will continue to enhance the quality management of its oral healthcare services and improve its existing medical quality management system [2] Group 2: Business Strategies - In 2025, the company will increase the development of new products and processes in the permanent magnet switch business, optimizing product design to enhance quality and performance [2] - The company aims to expand its market presence by focusing on both regional and industry operations, as well as channel sales [1] Group 3: Financial Management - The company will adhere to accounting standards for impairment provisions, ensuring sustainable development [3] - The company has not yet received the detailed equity change report from the information disclosure obligor [3][4] Group 4: Shareholder Engagement and Future Plans - The company is considering the acquisition of quality assets in the oral healthcare sector and may divest from other businesses to strengthen its core dental services [3] - The company has expanded its dental clinic area by nearly 10,000 square meters and increased the number of dental chairs by over 100 [5]

Group 1 - The core viewpoint of the news is that Haocen Medical has shown a slight increase in stock price and has a market capitalization of 2.318 billion yuan, with a current price-to-book ratio of 6.07 [1] - On May 27, Haocen Medical's main funds saw a net inflow of 86,000 yuan, with a total inflow of 6.7166 million yuan over the past five days [1] - The company specializes in oral medical services and the research, production, and sales of permanent magnet switches and high/low voltage complete equipment [1] Group 2 - In the latest performance report for Q1 2025, Haocen Medical achieved operating revenue of 143 million yuan, a year-on-year decrease of 12.58%, and a net profit of -12,214,580.55 yuan, a year-on-year decrease of 167.13%, with a gross profit margin of 38.50% [1] - The company has recently received several honors, including two new authorized invention patents, three new utility model patents, and various certifications related to energy management and measurement management [1] - The company's PE (TTM) is -51.14, and the industry average PE (TTM) is 38.66, indicating a significant disparity in valuation compared to industry peers [2]

为进一步加强与投资者的互动交流，皓宸医疗科技股份有限公司（以下简 称"公司"）将参加由吉林省证券业协会、深圳市全景网络有限公司共同举办 的"2025年吉林辖区上市公司投资者网上集体接待日活动"，现将有关事项公 告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演 APP,参与本次互动交流。活动时间为 2025年5月27日（周二）15:00- 16:30。届时公司董事长、总经理（代）陆璐女士，副总经理、财务总监邓强先 生，董事、副总经理、董事会秘书康超先生，独立董事姜琳女士将就公司2024 年度业绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者进 行沟通与交流，欢迎广大投资者踊跃参与！ 证券代码：002622 证券简称：皓宸医疗 公告编号：2025-014 皓宸医疗科技股份有限公司 关于参加2025年吉林辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特此公告。 皓宸医疗科技股份有限公司董事会 ...

证券代码:002622 证券简称：皓宸医疗 公告编号：2025-013 皓宸医疗科技股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东大会未出现否决提案的情形。 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开情况 （1）会议时间：2025 年 5 月 16 日（星期五）下午 14 点 45 分 （2）会议地点：吉林省吉林市船营区迎宾大路 98 号公司会议室 （1）现场会议出席情况 通过现场投票的股东 2 人，代表股份 30,000 股，占公司有表决权股份总数 的 0.0036％。 （2）通过网络投票股东参与情况 通过网络投票的股东 218 人，代表股份 206,592,300 股，占公司有表决权股 份总数的 24.5943％。 （3）参加投票的中小投资者情况 （3）会议召开方式：采取现场投票和网络投票相结合的方式 （4）会议召集人：皓宸医疗科技股份有限公司董事会 （5）会议主持人：公司董事长陆璐女士 本次大会的召开符合《公司法》和《公司章程》的有关规 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 2024年度股东大会的法律意见书 致：皓宸医疗科技股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受皓宸医疗科技股份有 限公司（以下简称"公司"）的委托，指派本所律师列席公司于 2025 年 5 月 16 日下午 14:45 在吉林省吉林市船营区迎宾大路 98 号公司会议室召开的公司 2024 年度股东大会（以下简称"本次股东大会"），并依据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司股东大会规则》等中国现行法律、法规和 其他规范性文件（以下简称"中国法律法规"）及《皓宸医疗科技股份有限公司 章程》（以下简称"《公司章程》"）的规定，就本次股东大会的召集和召开程 序、出席会议人员资格、召集人资格、会议表决程序和表决结果等事宜（以下简 称"程序事宜"）出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东大会的文件， 包括但不限于公司第五届董事会第十四次会议决议 ...

Core Insights - The medical beauty sector experienced a slight increase of 0.53% on May 8, with a total capital outflow of 224.7 million [1] - A total of 43 stocks in the sector rose, while 21 stocks declined [1] Top Gainers - The top ten gainers in the sector included: - Aipeng Medical: +13.1% - Haochen Medical: +9.85% - Guangyunda: +9.8% - ST Jingfeng: +5.01% - ST Biological: +4.98% - Hangzhou Jiebai: +4.34% - Langzi Co.: +4.11% - Hanyu Pharmaceutical: +2.7% - Xinyaqiang: +1.57% - Dezhan Health: +1.29% [1] Top Losers - The stocks with the largest declines included: - Hanshang Group: -9.99% - Lafang Cosmetics: -6.79% - Changshan Pharmaceutical: -5.7% - ST Suwu: -4.84% - Chaohongji: -4.75% [1]

每经评论员杜宇 皓宸医疗仍需面对诸多不确定性和挑战。首先，管理层的调整和战略方向的改变需要时间来落地实施， 短期内可能难以看到明显的业绩改善。其次，公司长期的业绩低迷已经让其在二级市场上的表现大打折 扣。要恢复投资者的信心并非易事，公司需要在业绩提升和市场拓展方面拿出切实可行的方案。 此外，控制权变更后，公司内部的整合和协调也需要时间和精力。新的管理层需要迅速熟悉公司业务， 与现有团队进行有效沟通和协作，避免因管理不善导致的内部矛盾和效率低下。同时，公司在市场竞争 中的地位并未因控制权变更而自动提升，仍需面对激烈的市场竞争和行业挑战。 对于皓宸医疗而言，控制权变更既带来了新的机遇，也带来了新的挑战。笔者认为，公司需要抓住这一 契机，通过优化管理、提升业绩、拓展市场等方式，实现破局重生。同时，公司还需要加强内部管理， 优化业务流程，提升产品和服务质量，逐步改善财务状况。 5月7日晚间，皓宸医疗（002622）(SZ002622，前收盘价：2.64元，市值：22.18亿元)发布公告称，公司 第一大股东汇垠日丰的执行事务合伙人汇垠澳丰收到《民事判决书》，其与北京首拓融汇的合作协议被 正式解除。这一判决意味着汇垠澳丰 ...